These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 19384087

  • 1. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.
    Patel RR.
    Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087
    [Abstract] [Full Text] [Related]

  • 2. [Heart failure with thiazolidinedione treatment: what do we know today?].
    Erdmann E.
    Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
    [Abstract] [Full Text] [Related]

  • 3. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
    Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R, American Heart Association, American Diabetes Association.
    Circulation; 2003 Dec 09; 108(23):2941-8. PubMed ID: 14662691
    [No Abstract] [Full Text] [Related]

  • 4. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE, Hanna A.
    Diabetes Obes Metab; 2008 Apr 09; 10(4):312-28. PubMed ID: 18333890
    [Abstract] [Full Text] [Related]

  • 5. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB.
    Pharmacotherapy; 2006 Feb 09; 26(2):168-81. PubMed ID: 16466323
    [Abstract] [Full Text] [Related]

  • 6. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD, Parlan G, Bailey AL, Yee G, Yu M, Chan JY.
    Clin Ther; 2009 Jan 09; 31(1):74-88. PubMed ID: 19243708
    [Abstract] [Full Text] [Related]

  • 7. [Heart failure while taking glitazones--what do we know today?].
    Halbritter R.
    Dtsch Med Wochenschr; 2009 Jul 09; 134(28-29):1488; author reply 1488. PubMed ID: 19572255
    [No Abstract] [Full Text] [Related]

  • 8. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U, Pop-Busui R, Eagle KA.
    Ann Pharmacother; 2008 Oct 09; 42(10):1466-74. PubMed ID: 18698014
    [Abstract] [Full Text] [Related]

  • 9. Thiazolidinediones in type 2 diabetes--have they lived up to expectations?
    Bhansali A, Modi P.
    J Indian Med Assoc; 2005 Jun 09; 103(6):343-6. PubMed ID: 16225162
    [Abstract] [Full Text] [Related]

  • 10. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
    De Flines J, Scheen AJ.
    Rev Med Suisse; 2007 Aug 29; 3(122):1876, 1878-83. PubMed ID: 17896661
    [Abstract] [Full Text] [Related]

  • 11. The role of glitazones in management of type 2 diabetes. A dream or a nightmare?
    Lindberg M, Astrup A.
    Obes Rev; 2007 Sep 29; 8(5):381-4. PubMed ID: 17716295
    [Abstract] [Full Text] [Related]

  • 12. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.
    Fonarow GC.
    Am Heart J; 2004 Oct 29; 148(4):551-8. PubMed ID: 15459582
    [Abstract] [Full Text] [Related]

  • 13. PPARgamma agonists: safety issues in heart failure.
    Tang WH, Maroo A.
    Diabetes Obes Metab; 2007 Jul 29; 9(4):447-54. PubMed ID: 17587386
    [Abstract] [Full Text] [Related]

  • 14. Balancing risk and benefit with oral hypoglycemic drugs.
    Hamnvik OP, McMahon GT.
    Mt Sinai J Med; 2009 Jun 29; 76(3):234-43. PubMed ID: 19421967
    [Abstract] [Full Text] [Related]

  • 15. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure.
    Erdmann E, Wilcox RG.
    Eur Heart J; 2008 Jan 29; 29(1):12-20. PubMed ID: 18167366
    [Abstract] [Full Text] [Related]

  • 16. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
    Patel C, Wyne KL, McGuire DK.
    Diab Vasc Dis Res; 2005 May 29; 2(2):61-6. PubMed ID: 16305060
    [Abstract] [Full Text] [Related]

  • 17. Diabetes and heart failure: the role of thiazolidinediones in managing these partners in crime.
    Leier CV, Haas GJ.
    J Am Coll Cardiol; 2007 Jul 03; 50(1):37-9. PubMed ID: 17601543
    [No Abstract] [Full Text] [Related]

  • 18. Thiazolidinedione-induced edema in patients with heart failure.
    Stroup JS.
    Am J Health Syst Pharm; 2007 Dec 01; 64(23):2426-30; author reply 2430. PubMed ID: 18029947
    [No Abstract] [Full Text] [Related]

  • 19. Cardiovascular risk of rosiglitazone: another perspective.
    Waksman JC.
    J Pharm Pharmacol; 2008 Dec 01; 60(12):1573-82. PubMed ID: 19000361
    [Abstract] [Full Text] [Related]

  • 20. Research profile. Is there a link? TZDs and congestive heart failure. Andrew Karter, PhD.
    Kordella T.
    Diabetes Forecast; 2004 Jun 01; 57(6):98-100. PubMed ID: 15195634
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.